Abstract
Celecoxib (Celebrex) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.
MeSH terms
-
3-Phosphoinositide-Dependent Protein Kinases
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Celecoxib
-
Cyclooxygenase 2 Inhibitors / chemistry
-
Cyclooxygenase 2 Inhibitors / therapeutic use*
-
Humans
-
Molecular Structure
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / metabolism
-
Pyrazoles / chemistry
-
Pyrazoles / therapeutic use*
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases / antagonists & inhibitors
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
-
Sulfonamides / chemistry
-
Sulfonamides / therapeutic use*
Substances
-
Antineoplastic Agents
-
Cyclooxygenase 2 Inhibitors
-
Pyrazoles
-
Sulfonamides
-
3-Phosphoinositide-Dependent Protein Kinases
-
Protein Serine-Threonine Kinases
-
Sarcoplasmic Reticulum Calcium-Transporting ATPases
-
Celecoxib